Genomics of Drug Sensitivity in Cancer |
Olaparib
|
Synonyms |
AZD2281, KU0059436, Lynparza
|
Targets |
PARP1, PARP2
|
Target pathway |
Genome integrity
|
PubCHEM ID |
23725625
|
Jsmol |
|
Download molecule |
23725625
|
PUBCHEM IUPAC INCHI |
InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
|
Smiles |
FC5(=C(C(=O)N2(CCN(C(=O)C1(CC1))CC2))C=C(CC3(=NNC(=O)C4(=C3C=CC=C4)))C=C5)
|
Cluster number |
6
|
calculated LogS |
-4,454
|
Molecular weight |
434,47
|
calculated LogP |
3,1669
|
H-Acceptors |
7
|
H-Donors |
1
|
Ro5 violations |
0
|
Druglikeness |
8,3247
|
DrugScore |
0,641263495452684
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,4441
|
Rat Acute Toxicity |
2,5285
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,5191
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,5022
|
AMES Toxicity |
Non AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,4782
|